69 related articles for article (PubMed ID: 9935165)
1. Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study.
Pfosser A; Brandl M; Salih H; Grosse-Hovest L; Jung G
Int J Cancer; 1999 Feb; 80(4):612-6. PubMed ID: 9935165
[TBL] [Abstract][Full Text] [Related]
2. CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation.
Willems A; Schoonooghe S; Eeckhout D; De Jaeger G; Grooten J; Mertens N
Cancer Immunol Immunother; 2005 Nov; 54(11):1059-71. PubMed ID: 15891885
[TBL] [Abstract][Full Text] [Related]
3. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
Kufer P; Mack M; Gruber R; Lutterbüse R; Zettl F; Riethmüller G
Cancer Immunol Immunother; 1997; 45(3-4):193-7. PubMed ID: 9435872
[TBL] [Abstract][Full Text] [Related]
4. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
[No Abstract] [Full Text] [Related]
5. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
[TBL] [Abstract][Full Text] [Related]
6. Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.
Mølgaard K; Harwood SL; Compte M; Merino N; Bonet J; Alvarez-Cienfuegos A; Mikkelsen K; Nuñez-Prado N; Alvarez-Mendez A; Sanz L; Blanco FJ; Alvarez-Vallina L
Cancer Immunol Immunother; 2018 Aug; 67(8):1251-1260. PubMed ID: 29869168
[TBL] [Abstract][Full Text] [Related]
7. T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.
Wooldridge JE; Dahle CE; Weiner GJ
Cancer Immunol Immunother; 1997; 45(3-4):174-9. PubMed ID: 9435867
[TBL] [Abstract][Full Text] [Related]
8. Approaches to implement bispecific antibody treatment of ovarian carcinoma.
Canevari S; Mezzanzanica D; Mazzoni A; Negri DR; Figini M; Ramakrishna V; Bolis G; Colnaghi MI
Cancer Immunol Immunother; 1997; 45(3-4):187-9. PubMed ID: 9435870
[No Abstract] [Full Text] [Related]
9. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.
Bluemel C; Hausmann S; Fluhr P; Sriskandarajah M; Stallcup WB; Baeuerle PA; Kufer P
Cancer Immunol Immunother; 2010 Aug; 59(8):1197-209. PubMed ID: 20309546
[TBL] [Abstract][Full Text] [Related]
10. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.
Kroesen BJ; Nieken J; Sleijfer DT; Molema G; de Vries EG; Groen HJ; Helfrich W; The TH; Mulder NH; de Leij L
Cancer Immunol Immunother; 1997; 45(3-4):203-6. PubMed ID: 9435874
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibody treatment of murine B cell lymphoma.
De Jonge J; Heirman C; De Veerman M; Van Meirvenne S; Demanet C; Brissinck J; Thielemens K
Cancer Immunol Immunother; 1997; 45(3-4):162-5. PubMed ID: 9435864
[TBL] [Abstract][Full Text] [Related]
12. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement.
Chen L; Qian W; Pan F; Li D; Yu W; Tong L; Yang Y; Xu Q; Ding J; Dai R; Xian W; Zhu X; Ren P; Zhu H
Immunotherapy; 2024 Feb; 16(3):143-159. PubMed ID: 38126157
[TBL] [Abstract][Full Text] [Related]
13. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Geiger M; Stubenrauch KG; Sam J; Richter WF; Jordan G; Eckmann J; Hage C; Nicolini V; Freimoser-Grundschober A; Ritter M; Lauer ME; Stahlberg H; Ringler P; Patel J; Sullivan E; Grau-Richards S; Endres S; Kobold S; Umaña P; Brünker P; Klein C
Nat Commun; 2020 Jun; 11(1):3196. PubMed ID: 32581215
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action.
Hirschhaeuser F; Walenta S; Mueller-Klieser W
Cancer Immunol Immunother; 2010 Nov; 59(11):1675-84. PubMed ID: 20652245
[TBL] [Abstract][Full Text] [Related]
15. A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity.
Sugiyama A; Umetsu M; Nakazawa H; Niide T; Onodera T; Hosokawa K; Hattori S; Asano R; Kumagai I
Sci Rep; 2017 Jun; 7(1):2862. PubMed ID: 28588218
[TBL] [Abstract][Full Text] [Related]
16. Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma.
Grab AL; Kim PS; John L; Bisht K; Wang H; Baumann A; Van de Velde H; Sarkar I; Shome D; Reichert P; Manta C; Gryzik S; Reijmers RM; Weinhold N; Raab MS
Cells; 2024 May; 13(10):. PubMed ID: 38786100
[TBL] [Abstract][Full Text] [Related]
17. Diabodies: small bispecific antibody fragments.
Holliger P; Winter G
Cancer Immunol Immunother; 1997; 45(3-4):128-30. PubMed ID: 9435855
[No Abstract] [Full Text] [Related]
18. Rapid Access to Potent Bispecific T Cell Engagers Using Biogenic Tyrosine Click Chemistry.
Shajan I; Rochet LNC; Tracey SR; Jackowska B; Benazza R; Hernandez-Alba O; Cianférani S; Scott CJ; van Delft FL; Chudasama V; Albada B
Bioconjug Chem; 2023 Dec; 34(12):2215-2220. PubMed ID: 37962868
[TBL] [Abstract][Full Text] [Related]
19. Bispecific antibody boosts dendritic cell-T cell crosstalk.
Crunkhorn S
Nat Rev Drug Discov; 2024 Mar; 23(3):170. PubMed ID: 38297091
[No Abstract] [Full Text] [Related]
20. Clinical perspectives of bispecific antibodies in cancer.
de Gast GC; van de Winkel JG; Bast BE
Cancer Immunol Immunother; 1997; 45(3-4):121-3. PubMed ID: 9435853
[No Abstract] [Full Text] [Related]
[Next] [New Search]
